ALTHX Stock Overview
A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Theranexus Société Anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.08 |
| 52 Week High | €2.24 |
| 52 Week Low | €0.63 |
| Beta | 2.34 |
| 1 Month Change | 3.35% |
| 3 Month Change | 45.95% |
| 1 Year Change | -25.00% |
| 3 Year Change | -91.26% |
| 5 Year Change | -81.31% |
| Change since IPO | -93.37% |
Recent News & Updates
Shareholder Returns
| ALTHX | FR Pharmaceuticals | FR Market | |
|---|---|---|---|
| 7D | 0.5% | -1.7% | -0.9% |
| 1Y | -25.0% | -9.4% | 6.6% |
Return vs Industry: ALTHX underperformed the French Pharmaceuticals industry which returned -9.4% over the past year.
Return vs Market: ALTHX underperformed the French Market which returned 6.6% over the past year.
Price Volatility
| ALTHX volatility | |
|---|---|
| ALTHX Average Weekly Movement | 12.7% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.6% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALTHX's share price has been volatile over the past 3 months.
Volatility Over Time: ALTHX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 19 | Mathieu Charvériat | www.theranexus.com |
Theranexus Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was founded in 2013 and is headquartered in Lyon, France.
Theranexus Société Anonyme Fundamentals Summary
| ALTHX fundamental statistics | |
|---|---|
| Market cap | €8.38m |
| Earnings (TTM) | -€6.83m |
| Revenue (TTM) | €319.00k |
26.3x
P/S Ratio-1.2x
P/E RatioIs ALTHX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALTHX income statement (TTM) | |
|---|---|
| Revenue | €319.00k |
| Cost of Revenue | €5.08m |
| Gross Profit | -€4.76m |
| Other Expenses | €2.07m |
| Earnings | -€6.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 26, 2024
| Earnings per share (EPS) | -0.88 |
| Gross Margin | -1,491.22% |
| Net Profit Margin | -2,140.44% |
| Debt/Equity Ratio | 147.3% |
How did ALTHX perform over the long term?
See historical performance and comparison